Dr. Konala is a general medical oncologist diagnosing and treating hematological disorders at George Cancer Specialists, a partner of Northside Hospital Cancer Institute. He is a fellow of the American College of Physicians and a certified anticoagulation provider. He is ABIM Board Certified in Internal Medicine and Medical Oncology.

Dr. Konala received a medical degree from Rangaraya Medical College in India. He trained in internal medicine at the Hospital of the University of Pennsylvania and completed a fellowship in hematology/oncology at the Texas Tech University Health Sciences Center at Lubbock.

As of September 2025, Dr. Konala reported no ongoing external relationships. 

Dr. Abdel-Karim is Chief of Staff at St. Bernard’s Healthcare and an attending physician in the Department of Hematology/Oncology at Cancer Care Associates in Jonesboro, Arkansas. Previously, he practiced at the Cooper Clinic in Fort Smith, Arkansas, and served as an Assistant Professor in the Division of Hematology/Oncology at the University of Texas Health Science Center at San Antonio in Texas. He is ABIM Board Certified in Geriatric Medicine, Medical Oncology and Hematology.

Dr. Abdel-Karim received a medical degree from the University of Jordan and completed internal medicine training at the St. Vincent Charity Medical Center. He completed fellowships in geriatric medicine and combined hematology/oncology at the University of Texas Health Science Center San Antonio Joe and Teresa Lozano Long School of Medicine. He has a Master of Healthcare Administration from the University of Arkansas at Fort Smith.

As of April 2026, Dr. Abdel-Karim reported no ongoing external relationships.  

Dr. Badari is a hematologist oncologist practicing at Banner MD Anderson Cancer Center in Gilbert, Arizona. His focus is on hematologic malignancies and stem cell transplant and cellular therapies. He is ABIM Board Certified in Internal Medicine, Hematology and Medical Oncology.

Previously, Dr. Badari practiced as a hematologist/oncologist at Yuma Regional Cancer Center and at Ochsner Medical Center in New Orleans. His practice focused on complex hematologic malignancies as well as benign hematology patients, clinical research and clinical trials, as well as teaching medical students, residents and fellows. He held the title of Senior Lecturer at the University of Queensland (UQ)-Ochsner Clinical School, a collaboration between Ochsner Medical Center and the University of Queensland, Australia.

Dr. Badari obtained a medical degree from Bangalore Medical College and Research Institute and completed internal medicine residency training at the State University of New York (SUNY) at Buffalo. He pursued fellowship in geriatrics at the University of Wisconsin, Madison, and in hematology at SUNY Buffalo. He completed a fellowship in medical oncology at the University of Arizona. 

As of February 2026, Dr. Badari reported no ongoing external relationships.  

Dr. Beinart is a medical oncologist at the Medical Clinic of Houston and Houston Methodist, where is an Associate Professor of Clinical Medicine in the Academic Institute. He is ABIM Board Certified in Medical Oncology and Hematology.

Dr. Beinart’s research involves clinical trials of investigational new drugs for the treatment of various types of cancers, including pancreatic, breast, prostate and lung. He earned numerous honors during his medical education and postdoctoral training, including the Caplovitz Award for Outstanding Senior Student in Internal Medicine, the Baylor Alumni Award, membership in the Alpha Omega Alpha honor society and a MERIT Award for research from the American Society of Clinical Oncology (ASCO) Foundation.

Dr. Beinart received a medical degree from the Baylor College of Medicine. He completed internal medicine residency training at the University of California, San Francisco and trained in hematology/oncology at the MD Anderson Cancer Center through the University of Texas Health Science Center at Houston.

As of September 2025, Dr. Beinart reported no ongoing external relationships. 

Dr. Boulmay is a hematologist and medical oncologist at LSU Health New Orleans and Program Director for the Hematology/Oncology Fellowship at Louisiana State University. He is ABIM Board Certified in Internal Medicine, Hematology and Medical Oncology and his clinical interests are in head and neck, lung and other aerodigestive tumors.

Dr. Boulmay earned his medical degree from Louisiana State University. He completed his internship and residency in internal medicine as well as a fellowship in hematology/oncology at the University of Florida.

As of April 2026, Dr. Boulmay reported no ongoing external relationships.

Dr. Chew is a Professor of Medicine, Vice Chief of Hematology and Oncology, and Director of the Clinical Breast Cancer Program at the UC Davis Comprehensive Cancer Center in Sacramento. She is responsible for coordinating surgical, medical and radiation oncology services and clinical trials for breast cancer. Her research interests involve novel treatments for breast cancer, serum tumor markers, complications of cancer—including thromboembolism—and treatment-related cognitive dysfunction. She is ABIM Board Certified in Medical Oncology.

Dr. Chew received a medical degree from the University of Texas Medical School at San Antonio. She trained in internal medicine and hematology/oncology at the University of Texas Health Science Center San Antonio through the Joe R. and Teresa Lozano Long School of Medicine program.

As of September 2025, Dr. Chew reported the following external relationships:

Dr. Chew is a Professor of Medicine at the University of California, Davis.  

Dr. Eatrides is a hematologist/oncologist at Moffitt Cancer Canter and member of the Moffitt Medical Group in the Satellite and Community Oncology Department practicing at Tampa General Hospital. Her clinical interest is in hematologic malignancies. She is ABIM Board Certified in Internal Medicine, Hematology and Medical Oncology.

Dr. Eatrides earned a medical degree at the University of South Florida (USF) Morsani College of Medicine, where she also completed internal medicine training and a fellowship in hematology/oncology through the Moffitt Cancer Center and Tampa General Hospital program.

As of October 2025, Dr. Eatrides reported no ongoing external relationships.  

Dr. Karlin is a general medical oncologist at the Mayo Clinic Arizona and Associate Professor of Medicine of the Mayo Clinic College of Medicine and Sciences. She is ABIM Board Certified in Internal Medicine and Medical Oncology. Previously, Dr. Karlin was an internist at Weed Army Community Hospital at Fort Irwin, California, and at Blanchfield Army Community Hospital at Fort Campbell, Kentucky.

Dr. Karlin also serves on the ABIM Internal Medicine Traditional, 10-Year Maintenance of Certification (MOC) Exam Approval Committee. She has served on the Lifelong Learning Committee, Addressing Disparities in Older Adults Working Group and Ethics Committee of the American Society of Clinical Oncology. Locally, she is a member of the Mortality Committee and has previously served on the Space and Capital Committee, Humanities in Medicine Committee and Pharmacy Therapeutics Committee. She is core faculty and a member of program evaluation committees for the Hematology Oncology Fellowship and Internal Medicine Residency Programs and is a member of the Hematology Oncology Fellowship Clinical Competency Committee. She has active research with the Division of Endocrinology in cancer and diabetes.

Dr. Karlin received a bachelor's degree in classics and biology from Brown University, and her medical degree from Dartmouth. She completed her internal medicine training at William Beaumont Army Medical Center and a hematology oncology fellowship at University of California, Los Angeles Olive View Medical Center.

As of September 2025, Dr. Karlin reported no ongoing external relationships.

Dr. Michaelson is a clinical researcher and educator in urologic oncology and Program Director for the Hematology/Oncology Fellowship at Massachusetts General Hospital (MGH). He is also a co-program leader for the Kidney Cancer Program at the Harvard Cancer Center. His research focuses on developmental therapeutics in urologic oncology, with a focus on targeted therapy for advanced renal cell, prostate and bladder carcinomas. He maintains an active clinical practice consisting of patients with advanced urologic malignancies and has a well-established record of productive clinical and translational research projects and publications. He has served as principal investigator on numerous clinical trials in this field and participates in multiple national organizations and guideline panels focused on urologic cancers, including the National Comprehensive Cancer Network’s Kidney Cancer Panel and the NRG Oncology GU Steering Committee. He has also served on the ABIM Medical Oncology Item-Writing Task Force in Medical Oncology.

Previously, Dr. Michaelson was on faculty at the MGH Cancer Center. He is ABIM Board Certified in Medical Oncology.

Dr. Michaelson earned his medical degree and doctorate at Albert Einstein College of Medicine. He completed residency in internal medicine at Brigham and Women's Hospital followed by fellowship in medical oncology at Dana Farber/Mass General Brigham. 

As of September 2025, Dr. Michaelson reported the following external relationships: 

Service on a research-related expert panel or advisory board for the following companies, with compensation for travel expenses and honoraria:    

• Eisai  
• Janssen Pharmaceuticals 
• Merck  

Dr. Zuckerman is a medical oncologist at St. Luke’s Cancer Institute in Boise. He has a special interest in gastrointestinal cancers and colorectal cancer. He is ABIM Board Certified in Internal Medicine, Hematology and Medical Oncology. Dr. Zuckerman has published research in Cancer and The Journal of Clinical Oncology, and been recognized with the Outstanding Achievement Award in Medicine by the University of Chicago Pritzker School of Medicine, the Dunne Award by Brigham and Women’s Hospital and the Clinical Fellows Distinguished Excellence in Teaching Award by the Dana-Farber Cancer Institute.

Dr. Zuckerman earned a medical degree at the Pritzker School of Medicine. He completed internal medicine training at Massachusetts General Hospital/Brigham and Women’s Hospital followed by training in hematology/oncology through the Dana-Farber Cancer Institute. 

As of August 2025, Dr. Zuckerman reported the following external relationships:  

Service on a research-related advisory board for the following companies, with compensation for travel expenses and honoraria:    

• AstraZeneca  

Dr. Munster is Professor in Residence at the University of California, San Francisco, where she is also the Director of Early Phase Clinical Trials Program at the Helen Diller Family Comprehensive Cancer Center and Program Leader of Developmental Therapeutics. She is the co-Leader of the BRCA Center. Dr. Munster is ABIM Board Certified in Medical Oncology and also serves on the ABIM Medical Oncology Board.

She served at Memorial Sloan Kettering Cancer Center as a faculty member in the breast cancer program before joining the Division of Breast Oncology and Experimental Therapeutics Program at Moffitt Cancer Center and Research Institute in Tampa, Florida. Dr. Munster led the group as the Scientific Director of Breast Research and Co-Chair of the Phase I Program at Moffitt for six years prior to joining the University of California, San Francisco.

Her basic laboratory research interests are in the areas of developing novel targeted therapy for the treatment of treatment resistant cancer and their integration into current treatment strategies. Dr. Munster's research interest involves basic research studies on epigenetic modification of DNA repair and therapy resistance. Her laboratory is involved in several projects testing histone deacetylase inhibitors HDAC inhibitors reverse hormone therapy resistance in breast cancer and to reengage the immune defense. Dr. Munster's clinical research interests are in the areas of early anti-tumor drug development with focus on drugs that target the mTOR, P13k pathways and the epigenetic regulation of immune response to therapy. In addition to her interest in drug development, Dr. Munster has a special interest in the germline cancer mutations.

Dr. Munster has published in numerous scientific journals and has given lectures on topics such as the management of metastatic breast cancer, breast cancer receptors, clinical trials and translational research.

Dr. Munster received her medical degree from the University of Bern in Switzerland, completed her residency in internal medicine at Indiana University Medical Center and an oncology/hematology fellowship at Memorial Sloan Kettering Cancer Center.

As of April 2026, Dr. Munster reported the following external relationships:

Service on data and safety monitoring boards for the following companies, with compensation for travel expenses and honoraria:    

• Catalent Pharma Solutions  
• IQVIA, reviewing cases for safety in cardiology patients on a GLP-1 agonist.  

Dr. Munster earns domestic and international royalties regarding a healthcare-related patent from Alessa.     

Dr. Borghaei is the Chief of Thoracic Medical Oncology, Professor in the Department of Hematology/Oncology at Fox Chase Cancer Center and the Gloria and Edmund M. Dunn Chair in Thoracic Medical Oncology. Since completing his fellowship training at Fox Chase, he has been involved in a number of clinical trials aimed at developing new, antibody-based therapies and immunotherapies for patients with mung cancer.

In addition to his clinical practice and participation in immunotherapy-based clinical trials, Dr. Borghaei is the principal investigator of a laboratory that develops new monoclonal antibodies and novel immune-modulating drugs, with the aim of bringing these approaches to the clinic. He served as the principal investigator of a phase III randomized study that proved the effectiveness of nivolumab in the treatment of patients with advanced non-squamous non-small cell lung cancer after progression on prior chemotherapy. The work led to the approval of nivolumab, one of the first immunotherapy-based drugs to be approved for lung cancer in this setting.

Dr. Borghaei earned his degree at Philadelphia College of Osteopathic Medicine and completed a residency at Graduate Hospital in Philadelphia. He is ABIM Board Certified in Medical Oncology.

As of May 2026, Dr. Borghaei reported the following external relationships:

Funding for clinical trial expenses and staff, paid to Fox Chase Cancer Center, from the following companies:  

• Genentech  

Service on a research-related advisory board for the following companies, with compensation for travel expenses and honoraria:    

• Daiichi Sankyo Company  
• Gilead  
• Guardant  
• Inspirna  
• Janssen  
• Merck  
• Novocure  
• Nucleai  
• Raptor Research Foundation  
• Sonnet Bio  
• Summit Therapeutics   

Service on data and safety monitoring boards for the following companies, with honoraria:   

• Novartis  
• Servier Pharmaceuticals  

Consulting on the design of new drugs or devices, clinical trials, the use of specific agents or other research-related activities for the following companies, with compensation honoraria:   

• AbbVie  
• Amgen  
• Astellas Pharma  
• AstraZeneca  
• Boehringer Ingelheim  
• Bristol-Myers Squibb  
• Eli Lilly & Company  
• Genentech   
• Genmab  
• Gilead   
• Grid Therapeutics  
• Janssen Pharmaceuticals 
• Jazz Pharmaceuticals 
• Merck   
• PharmaMar  
• Regeneron  
• Systimmune  

Industry-supported continuing medical education supported by the following, with honoraria:  

• Pfizer  

Dr. Chmielowski is an Associate Clinical Professor of Medicine in the Division of Hematology-Oncology at the University of California, Los Angeles (UCLA).

He is ABIM Board Certified in Medical Oncology and Hematology. Dr. Chmielowski has been a UCLA faculty member since 2008, and his clinical and laboratory research concentrate on the development of new therapies for patients with melanoma, non-melanoma skin cancers and sarcoma. He has a special interest in the development of new immunotherapeutic agents and new combination immunotherapies not only in melanoma, but also in non-melanoma skin cancers and sarcoma including patients with gastrointestinal stromal tumors. In addition, he studies new molecularly targeted agents in both sarcoma and melanoma.

He graduated from Wrocław Medical University in Poland. He moved to the United States to pursue a research career in immunology at the Medical College of Georgia. He concentrated on studying T-cell development in the thymus, especially the processes of positive and negative selection. His research resulted in a doctoral thesis.

Dr. Chmielowski completed his residency in internal medicine at the Medical College of Georgia and his fellowship in hematology-oncology at UCLA.

As of March 2026, Dr. Chmielowski reported the following external relationships:

Service on data and safety monitoring boards for the following companies, with compensation for travel expenses and honoraria:  

• TuHURA Biosciences Inc.  
• Servier Affaires Medicales  

Dr. Jakob is a community-based adult hematologist oncologist at Summa Health Systems in Akron, Ohio, and a Clinical Associate Professor at Northeast Ohio Medical University. He is ABIM Board Certified in Medical Oncology and Hematology.

Dr. Jakob received a Bachelor of Arts at the College of the University of Chicago, and a medical degree and Doctor of Philosophy at Columbia University. His clinical training took place at University Hospitals Cleveland/Case Western Reserve University in internal medicine and the University of Texas MD Anderson Cancer Center in hematology and oncology.

As of April 2026, Dr. Jakob reported no ongoing external relationships.

Dr. Wirth is the Medical Director of the Head and Neck Oncology Program at Massachusetts General Hospital and an Associate Professor of Medicine at Harvard Medical School. Before joining Mass General in 2008, Dr. Wirth was on staff at the Dana-Farber Cancer Institute. She is ABIM Board certified in Medical Oncology.

Dr. Wirth serves as the Chairperson of the International Thyroid Oncology Program and sits on the National Comprehensive Cancer Network's Thyroid Carcinoma Guidelines Panel. She is also a member of the Dana-Farber/Harvard Cancer Center Scientific Review Committee. She has previously served on the Dana-Farber/Harvard Cancer Center Institutional Review Board and the National Cancer Institute's Head and Neck Cancer Steering Committee Recurrent/Metastatic Disease Task Force and has recently served on the American Joint Committee on Cancer's Endocrine Expert Panel.

Dr. Wirth received her bachelor's degree from Brown University and medical degree from Columbia University's College of Physicians and Surgeons. She completed her internal medicine residency at NewYork-Presbyterian Medical Center, Columbia Presbyterian and completed a three-year fellowship in the Dana-Farber/Partners CancerCare Hematology/Oncology Program.

As of September 2025, Dr. Wirth reported the following external relationships:

Consulting on the design of new drugs or devices, clinical trials, the use of specific agents or other research-related activities for the following companies, with honoraria:   

• Coherus, receiving honoraria.  
• Eisai, receiving honoraria.  
• Novartis, receiving honoraria.  
• PDS Biotechnology, receiving honoraria.  
• Pyxis, receiving honoraria.